Fiche du document
- doi: 10.1371/journal.ppat.1009169
- issn: 1553-7366
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.ppat.1009169
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33370407
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1553-7374
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_711970C96BE81
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Infectious diseases Immune globulins Antibodies Immune serum globulinCiter ce document
M. Perotti et al., « Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. », Serveur académique Lausannois, ID : 10.1371/journal.ppat.1009169
Métriques
Partage / Export
Résumé
Human cytomegalovirus (HCMV) is the primary viral cause of congenital birth defects and causes significant morbidity and mortality in immune-suppressed transplant recipients. Despite considerable efforts in vaccine development, HCMV infection still represents an unmet clinical need. In recent phase II trials, a MF59-adjuvanted gB vaccine showed only modest efficacy in preventing infection. These findings might be attributed to low level of antibodies (Abs) with a neutralizing activity induced by this vaccine. Here, we analyzed the immunogenicity of each gB antigenic domain (AD) and demonstrated that domain I of gB (AD5) is the main target of HCMV neutralizing antibodies. Furthermore, we designed, characterized and evaluated immunogenic responses to two different nanoparticles displaying a trimeric AD5 antigen. We showed that mice immunization with nanoparticles induces sera neutralization titers up to 100-fold higher compared to those obtained with the gB extracellular domain (gBECD). Collectively, these results illustrate with a medically relevant example the advantages of using a general approach combining antigen discovery, protein engineering and scaffold presentation for modern development of subunit vaccines against complex pathogens.